Fate Therapeutics, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-1
Book Value Per Share
$2
Free Cash Flow Per Share
$-1
Cash Per Share
$0
Revenue Per Share
$0
OCF Per Share
$-1
Return on Equity
-51.8%
Return on Assets
-35.9%
Return on Invested Capital
-44.4%
Debt to Equity
—
Current Ratio
5.79
Quick Ratio
5.79
Asset Turnover
0.02
Days Sales Outstanding
50.31
R&D / Revenue
1622.5%
SBC / Revenue
—
Capex / Revenue
89.6%
Working Capital
$173M
Net Current Asset Value
$209M
Invested Capital
$207M
OCF / Net Income
0.78
FCF / Net Income
0.82
Accruals Ratio (Sloan)
-9.5%
Net Debt
$-204M
Net Debt / EBITDA
1.51
Interest Coverage
—
Cash Coverage
—
Capex Coverage
-17.82
Tangible Common Equity
$207M
TCE / Total Assets
65.0%
NOPAT
$-117M
Cash ROIC
-42.6%
WC / Revenue
2597.5%
Capex / D&A
0.46
Reinvestment Rate
4.7%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
23.6%
Revenue 5Y CAGR
-26.7%
Book Value 5Y CAGR
-11.6%
Stock Price (FY-end)
$1
Market Cap
$116M
P/S Ratio
17.52
P/B Ratio
0.56
P/TB Ratio
0.56
Enterprise Value
$-87M
EV / Sales
-13.13
FCF Yield
-96.2%
R&D Yield
92.6%
Capex Yield
5.1%
Shares Variation (YoY)
4.5%
Beta (5Y)
1.73
Cost of Equity
13.2%
Cost of Debt (after tax)
—
52W High
$2
52W Low
$1
Trailing Return 1Y
-39.1%
Trailing Return 5Y
-99.0%
F-Score (Piotroski)
1.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.